Novartis AG to buy immunology specialist Calypso Biotech BV
Upon closure, the US$425m take-over of the Amsterdam-headquartered Calypso Biotech NV, would give Novartis AG full commercialisation rights to...
Bayer SE secures rights to in €310m deal
Under the licence deal, BridgeBio Pharma, Inc. will pass the commercialisation rights for the transthyretin stabiliser acoramidis in Europe where...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Spexis sells antibiotics programme to Basilea
Spexis AG (Alschwil) has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd. Under the agreement Basilea will acquire a...
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Existing investors including Claris Ventures and angel investors participated in the financing The proceeds will be used to initiate and complete the...
Curve Therapeutics raises £40.5m in Series A financing
New investors Columbus Venture Partners and British Patient Capital and founding investor Advent Life Sciences as well as seed investor Epidarex...
Vandria SA bags CHF18m in Series A financing
agSwiss Vandria SA said it will use the proceeds from a CHF18m Series A financing led by ND Capital and a syndicate of HNW private investors to...